Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees.  The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals, Inc. adalah perusahaan bioteknologi global yang terlibat dalam bisnis menemukan, mengembangkan, memproduksi, dan memasarkan obat-obatan molekul kecil untuk pasien dengan penyakit serius. Perusahaan berkantor pusat di Boston, Massachusetts dan saat ini mempekerjakan 6.400 karyawan penuh waktu. Perusahaan memiliki tujuh obat yang disetujui: lima yang mengobati penyebab mendasar fibrosis kistik (CF), satu yang mengobati penyakit sel sabit parah (SCD) dan talasemia beta tergantung transfusi (TDT), dan satu yang mengobati nyeri akut sedang hingga parah. Pipa pengembangan produknya mencakup program tahap klinis dalam CF, SCD, talasemia beta, nyeri neuropatik akut dan perifer, penyakit ginjal mediasi APOL1, nefropati IgA dan penyakit ginjal autoimun lainnya serta sitopenia, diabetes tipe 1, distrofi miotonik tipe 1, dan penyakit ginjal polikistik autosomal dominan. Obat-obatan yang dipasarkan termasuk TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor dan ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor dan ivacaftor), ORKAMBI (lumacaftor/ivacaftor), dan KALYDECO (ivacaftor).

Vertex Pharmaceuticals

Google

Apple

Microsoft

Amazon

Broadcom

Meta Platforms

Eli Lilly

JPMorgan

Oracle

Exxon Mobil

Johnson & Johnson

ASML

MasterCard

SPDR S&P500 ETF

Palantir

Costco

Bank of America

General Electric

Procter & Gamble

Vanguard Total Stock Market ETF

Toyota

Caterpillar

AstraZeneca

Cisco

Goldman Sachs

Lam Research

Wells Fargo

Merck

Novo Nordisk

Novartis

Raytheon Technologies

Philip Morris

Applied Materials

American Express

Royal Bank of Canada

Intel

Abbott

Salesforce

Shell

T-Mobile

Intuitive Surgical

Disney

Shopify

Invesco QQQ Trust

Blackstone

PepsiCo

Boeing

Charles Schwab

Amgen

QUALCOMM

Texas Instruments

S&P Global

Verizon

Arista Networks

Lowe's

Capital One

Southern Copper

Honeywell

Sony

Pfizer

Unilever

Deere

TotalEnergies

ServiceNow

Adobe

Palo Alto Networks

ConocoPhillips

Medtronic

Progressive

Chubb

CrowdStrike

Sanofi

Bristol-Myers Squibb

Comcast

Vanguard Dev Markets ETF

Mercadolibre

Starbucks

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Robinhood

Moody's

Nike

Northrop Grumman

Vanguard Total Bond Market ETF

Duke Energy

Scotiabank

Barclays

Doordash Inc

Marsh & McLennan

NetEase

Vertex Pharmaceuticals Stock

About Vertex Pharmaceuticals

Key Statistics

People Also Bought